VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2022 | The association of the HER2DX signatures with survival in TNBC

Benedetta Conte, IDIBAPS, Barcelona, Spain, discusses the exploratory analysis evaluating the prognostic effect of the HER2DX assay, the score of which takes into account tumor size, nodal staging, and 4 gene expression signatures tracking immune infiltration, tumor cell proliferation, luminal differentiation, and the expression of the HER2 amplicon. HER2DX has been standardized and validated in HER2+ disease. In-silico analyses were conducted on various public datasets, demonstrating the B-cell immune signature is strongly prognostic in triple-negative breast cancer (TNBC), which could contribute to the development of biomarkers for de-escalating treatment in TNBC. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter